Kenvue
KVUE
$18.98
-0.21%
Kenvue Inc. is the world's largest pure-play consumer health company, generating over $15 billion in annual revenue from iconic brands like Tylenol, Listerine, Aveeno, and Neutrogena across categories including pain management, oral care, and skin health. Spun off from Johnson & Johnson in May 2023, Kenvue holds a dominant market position as a pure-play consumer health leader with unparalleled brand recognition and scale. The current investor narrative is dominated by the pending acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has created a near-term valuation floor while also raising questions about execution risk and regulatory approvals. Recent earnings beats and analyst upgrades have added positive momentum, but the stock remains under pressure from post-IPO volatility and sector headwinds.…
KVUE
Kenvue
$18.98
Related headlines
KVUE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.75 and implied upside of +4.1% versus the current price.
Average Target
$19.75
0 analysts
Implied Upside
+4.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Kenvue is covered by 12 analysts, with a consensus recommendation of 'hold' and a mean recommendation score of 2.79 (where 1 is strong buy and 5 is sell). The average target price is $19.75, implying a 4.1% upside from the current price of $18.98. The distribution leans neutral, with no strong bullish or bearish tilt, reflecting uncertainty around the Kimberly-Clark acquisition. The target price range spans from a low of $18.00 to a high of $23.00. The high target of $23.00 assumes successful completion of the acquisition at a premium or a standalone turnaround with margin expansion, while the low target of $18.00 prices in execution risks or a lower acquisition price. Recent analyst actions have been mixed, with Jefferies downgrading from Buy to Hold in January 2026, while others maintained Neutral/Equal Weight ratings. The wide spread between low and high targets ($5.00) indicates high uncertainty, typical for a stock in the midst of a major M&A event. The lack of strong bullish conviction suggests that the stock's near-term performance is tied to the acquisition outcome rather than fundamental improvements.
Drowning in data?
Find the real signal!
Bulls vs Bears: KVUE Investment Factors
Kenvue presents a mixed investment case: strong fundamental improvements in revenue growth (4.5% YoY) and margin expansion (operating margin up to 21.9%) are offset by the uncertainty surrounding the pending Kimberly-Clark acquisition and the stock's significant underperformance (-13.1% vs. S&P 500 +18.4% over 1 year). The bull case rests on the acquisition providing a valuation floor and potential premium, while the bear case centers on execution risk and a stretched payout ratio. The single most important tension is whether the acquisition closes successfully—if it does, the stock could re-rate toward the $23 high target; if it fails, downside to the $18 low target or below is likely. Currently, the evidence slightly favors the bull case given the improving fundamentals and attractive forward P/E of 15.3x, but the neutral analyst consensus and wide target spread ($18-$23) demand caution.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 4.5% YoY to $3.909B, accelerating from 3.3% in Q4 2025 and 2.9% in Q3 2025, indicating improving organic momentum across Self Care, Essential Health, and Skin Health segments.
- Significant Margin Expansion: Operating margin surged to 21.9% in Q1 2026 from 14.9% a year ago, while net margin improved to 12.1% from 8.6%, reflecting cost discipline and operating leverage as the company scales post-spin-off.
- Attractive Forward Valuation: Forward P/E of 15.3x represents a 30% discount to the trailing P/E of 22.3x and is well below the industry average of 22x, suggesting the market is pricing in conservative expectations that could expand if growth persists.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow of $1.823B provides ample liquidity for dividends (4.8% yield) and debt servicing, with a debt-to-equity ratio of 0.79 and current ratio of 0.96 indicating a solid balance sheet.
Bearish
- Acquisition Execution Risk: The Kimberly-Clark acquisition, announced in November 2025, faces regulatory approval risks and potential renegotiation; if the deal falls through, the stock could drop to the analyst low target of $18.00 or below.
- Underperformance vs. Market: KVUE's 1-year price change of -13.1% severely lags the S&P 500's +18.4% gain, indicating persistent negative sentiment and post-IPO volatility that may continue until the acquisition closes.
- High Dividend Payout Ratio: The payout ratio of 107.6% exceeds 100%, meaning the dividend is not fully covered by earnings, which could force a cut if free cash flow declines or if the acquisition requires capital allocation changes.
- Limited Analyst Conviction: Consensus rating is 'hold' with a mean score of 2.79 (close to neutral), and only 4.1% upside to the average target of $19.75, reflecting uncertainty about the acquisition outcome and lack of strong bullish catalysts.
KVUE Technical Analysis
Kenvue's price trend over the past year is a downtrend, with a 1-year price change of -13.1%, significantly underperforming the S&P 500's +18.4% gain. The current price of $18.98 sits at 58.5% of its 52-week range ($14.02 low to $22.87 high), indicating the stock is closer to the lower end of its range after a substantial decline from its highs. This positioning suggests the stock is in a recovery phase from its lows but has not yet reclaimed its previous highs, reflecting lingering bearish sentiment despite recent improvement. Short-term momentum has turned positive, with a 1-month price change of +5.4% and a 3-month change of +7.8%, both outpacing the S&P 500's 1-month and 3-month gains of 0.3% and 4.7%, respectively. This divergence from the longer-term downtrend could signal a potential trend reversal or a temporary pullback, especially given the stock's beta of 0.44, which indicates lower volatility than the market. The recent price action shows a breakout from the $17-$18 range in late June, with the stock now testing resistance near $19.50-$20.00. The 52-week low of $14.02 provides strong support, while the 52-week high of $22.87 represents key resistance. A breakout above $20 could signal a shift to a more bullish trend, while a breakdown below $17 would suggest renewed weakness. With a beta of 0.44, Kenvue is significantly less volatile than the market, meaning it tends to move less than the S&P 500, which may appeal to risk-averse investors but also limits upside in strong market rallies.
Beta
0.44
0.44x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$14-$23
Price range past year
Annual Return
-13.1%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | -0.5% |
| 3m | +7.8% | +4.9% |
| 6m | +10.3% | +9.7% |
| 1y | -13.1% | +18.4% |
| ytd | +9.6% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue trajectory shows steady growth, with Q1 2026 revenue of $3.909 billion, up 4.5% year-over-year from $3.741 billion in Q1 2025. This marks an acceleration from the 3.3% YoY growth seen in Q4 2025 ($3.78 billion) and the 2.9% growth in Q3 2025 ($3.764 billion). The growth is driven by the Self Care segment ($1.699 billion), which includes cough, cold, and allergy products, while Essential Health ($1.151 billion) and Skin Health & Beauty ($1.059 billion) also contribute. The improving growth trend supports the investment case, indicating that the company is gaining traction in its core markets. The company is profitable, with Q1 2026 net income of $474 million and a gross margin of 58.9%. Net margin improved to 12.1% in Q1 2026 from 8.6% in Q1 2025, while operating margin expanded to 21.9% from 14.9% over the same period. This margin expansion reflects cost discipline and operating leverage, and the current margins are healthy for the household & personal products industry, where gross margins typically range from 50-60%. Kenvue maintains a solid balance sheet with a debt-to-equity ratio of 0.79 and a current ratio of 0.96, indicating adequate liquidity. Free cash flow for Q1 2026 was $350 million, and trailing twelve-month free cash flow reached $1.823 billion, providing ample cash for dividends and debt servicing. The ROE of 13.7% is reasonable, and the company's ability to generate positive free cash flow consistently reduces reliance on external financing.
Quarterly Revenue
$3.9B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
58.9%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Since net income is positive ($474 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 22.3x, while the forward P/E is 15.3x, based on estimated EPS of $1.41. The significant discount of the forward P/E to the trailing P/E implies that the market expects earnings growth, which aligns with the improving margin trends. Compared to the industry average P/E of 22x (estimated from sector data), Kenvue's trailing P/E of 22.3x is roughly in line, but the forward P/E of 15.3x represents a 30% discount, suggesting the market is pricing in below-average growth expectations or the acquisition uncertainty. Historically, Kenvue's P/E has ranged from 17x to 35x over the past three years. The current trailing P/E of 22.3x is near the middle of this range, while the forward P/E of 15.3x is near the lower end. This suggests that the market is pricing in conservative expectations, potentially due to the pending acquisition by Kimberly-Clark, which caps upside but also provides a floor. The PEG ratio of 0.52 indicates that the stock is undervalued relative to its growth rate, supporting a bullish view on valuation.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Kenvue's debt-to-equity ratio of 0.79 is manageable, but the payout ratio of 107.6% indicates the dividend is not fully covered by earnings, posing a risk of reduction if free cash flow weakens. The current ratio of 0.96 suggests tight liquidity, though the $1.823B trailing free cash flow provides a buffer. Revenue concentration in consumer health categories (Self Care, Essential Health, Skin Health) exposes the company to shifts in consumer spending and competitive pressures, though diversification across brands like Tylenol and Listerine mitigates this. The net margin of 12.1% is healthy but could compress if input costs rise or pricing power erodes.
Market & Competitive Risks: The stock's beta of 0.44 indicates low market correlation, but its 1-year underperformance (-13.1% vs. S&P 500 +18.4%) reflects sector rotation away from consumer staples and post-IPO volatility. The pending acquisition by Kimberly-Clark introduces regulatory and execution risk; if the deal fails, the stock could fall to the 52-week low of $14.02, a 26% downside. Competitive threats from larger players like Procter & Gamble and Unilever could pressure market share, though Kenvue's pure-play focus and iconic brands provide a moat. Recent news of analyst downgrades (Jefferies to Hold) and technical overbought conditions add near-term headwinds.
Worst-Case Scenario: If the Kimberly-Clark acquisition collapses due to regulatory hurdles or financing issues, and the company fails to sustain its margin improvements, the stock could retest its 52-week low of $14.02, representing a 26% decline from the current price of $18.98. In a severe recession, consumer spending on health and beauty products could decline, compressing revenue growth below 2% and margins back to 2024 levels, potentially driving the stock to $12-$13 based on historical P/E troughs. This scenario would result in a loss of 32-37% from current levels.
